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MicroRNAs (miRs) are involved in key biological processes via suppression of gene expression at posttranscriptional levels.
According to their superior functions, subtle modulation of miR expression by certain compounds or nutrients is desirable under
particular conditions. Bacterial lipopolysaccharide (LPS) induces a reactive oxygen species-/NF-κB-dependent pathway which
increases the expression of the anti-inﬂammatory miR-146a. We hypothesized that this induction could be modulated by the
antioxidantubiquinol-10.PreincubationofhumanmonocyticTHP-1cellswithubiquinol-10reducedtheLPS-inducedexpression
level of miR-146a to 78.9 ± 13.22%. In liver samples of mice injected with LPS, supplementation with ubiquinol-10 leads to a
reduction of LPS-induced miR-146a expression to 78.12 ± 21.25%. From these consistent in vitro and in vivo data, we conclude
that ubiquinol-10 may ﬁne-tune the inﬂammatory response via moderate reduction of miR-146a expression.
Copyright © 2009 Constance Schmelzer et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
MicroRNAs (miRs) are endogenous ∼22 nucleotide non-
coding RNAs which suppress gene expression at posttran-
scriptional levels by binding to the 3 -untranslated region of
speciﬁcmRNAtargetsthroughbasepairing[1].Anumberof
recent studies reveal that miRs have critical functions in key
biological processes such as cell proliferation and cell death
during development [2], fat metabolism [3, 4], or insulin
secretion [5]. Expression proﬁling approaches implicated a
diﬀerential expression of several miRs in cancer cells [1].
Regulated expression of miRs is scarcely understood but is
of special interest in the context of innate immunity and
inﬂammation [6]. Expression proﬁling of more than 200
miRs in human monocytic THP-1 cells revealed that miR-
146a is substantially inducible by LPS or other Toll-like
receptor ligands [7]. Moreover, promoter analysis of the
miR-146a gene suggests a role of NF-κBi nL P S - d e p e n d e n t
upregulation of miR-146a [7].
Modulation of the LPS→reactive oxygen species→NF-
κB signalling pathway and dependent miR-146a expression
could be an approach in order to ﬁne-tune the inﬂammatory
response. The importance of such a modulation is of
special interest because the balance between pro- and anti-
inﬂammatory signals is critical in certain inﬂammatory dis-
eases such as atherosclerosis. Here we hypothesized that the
reduced form of Coenzyme Q10 (QH2, ubiquinol-10) aﬀects
LPS-inducible expression of the anti-inﬂammatory miR-
146a. The hypothesis was based on functions of CoQ10 as a
potent antioxidant and putative modulator of inﬂammation
via gene expression [8, 9]. In the present work, we tested our
hypothesis using an in vitro and an in vivo model. Initially,2 Mediators of Inﬂammation
we utilized the human monocytic cell line THP-1 as a well-
established model of LPS-induced miR-146a expression and
applied ubiquinol-10. Additionally, liver samples of LPS-
injected mice supplemented with ubiquinol-10 were used to
strengthen the hypothesis that ubiquinol-10 has a relevance
in ﬁne-tuning LPS-induced miR-146a expression levels.
2.MaterialsandMethods
2.1. Reagents. Ubiquinol-10 aqueous solution (PEG-60
hydrogenated castor oil, ubiquinol-10, glycerol, water) and
corresponding vehicle (no ubiquinol-10 supplement) were
purchased from KANEKA Corporation, Japan. Lipopolysac-
charide (LPS, E. coli O55:B5) was obtained from Sigma-
Aldrich (Germany).
2.2. Cell Culture. THP-1 cells were routinely cultivated in
RPMI medium 1640 supplemented with 10% FCS and
1% antibiotics (penicillin/streptomycin) in a humidiﬁed
incubator containing 5% CO2 at 37◦C. Twenty four hours
before preincubation, cells were plated at a density of 1 ×
106 cells per well in a 6-well plate. Subsequently, cells were
preincubated with 10μM ubiquinol-10 or the respective
vehicle control. After 24 hours, cell culture medium was
removed and fresh LPS-containing medium (1μg/mL) was
added for 4 hours. Finally, cells were collected in Qiazol-
lysis buﬀer (Qiagen, Germany) for isolation of total RNA or
alternatively scraped in Phosphate Buﬀered Saline (PBS) for
HPLC-analysis.
2.3. Animals. Male C57/BL6J mice (10–12 weeks old, 25g
weight) were purchased from Charles River Lab., Inc., Japan.
Animals were separated into two groups: (1) intervention
group (n = 6), which was given a diet enriched with
ubiquinol-10 (QH2, 250mg/kg/d) for one week and (2) the
control group (n = 6), which received a diet prepared
by using corn oil in equal proportions to 1% (v/w) of
the diet as a vehicle. In other respects all animals were
maintained on a standard laboratory diet (powdered CE-
2, CREA Japan) and housed under conditions at 22 ± 2◦C
witha12-hourlight/darkcycle.Foodintakeandbodyweight
were monitored daily but indicated no relevant diﬀerences
betweenanimals.Afterthe7-daysupplementationorcontrol
diet period, an intraperitoneal injection (1mg/kg BW) of
lipopolysaccharide (LPS, E. coli, O55:B5, Sigma-Aldrich,
Japan) was administered for further 4hours. However, for
HPLC-experiments, only saline-injected mice were used. In
all other aspects, animal treatment was identical. Subse-
quently, all mice were sacriﬁced, and liver samples were
collected and stored at −80◦Ci nR N A l a t e rS t o r a g eS o l u t i o n
(Qiagen, Japan) until use.
2.4. Cytotoxicity of THP-1 Cells. Determination of cell via-
bility was performed using the Cell-Titer Glo Luminescent
Assay.Thus,thetotalATPlevelsweremeasuredasanindexof
the viable cell number. The luminescence was detected on a
GloMax (Promega). Data (Figure 1)a r em e a n s± SD of three
biological experiments performed in triplicate.
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Figure 1: Eﬀect of ubiquinol-10 on viability of THP-1 monocytes.
THP-1 cells were treated with medium, 0.1–100μM ubiquinol-10,
or 10% DMSO (PC, positive control) for 24hours. Afterwards,
cell viability was determined based on ATP measurements. The
viability of medium control was set to 100%, and the other values
were referenced to it. Data are means ± SD of three independent
experiments performed in triplicate.
2.5. Determination of CoQ10 In Vitro and In Vivo. The
diﬀerent treated cells of each well were washed with
Phosphate Buﬀered Saline (PBS) and counted with Trypan
blue at −80◦C before measurement of cellular CoQ10.L i v e r
homogenatesof10QH2-supplementedornonsupplemented
mice (5 from each group, resp.) were stored at −80◦C( i n
0.9%sodium chloride, 10mg/mL) until furtheranalysis.The
method is based on high-pressure liquid chromatography
(HPLC) with electrochemical detection and internal stan-
dardisation using ubihydroquinone-9 and ubiquinone-9 as
standardsandisdescribedelsewhere[10].Inbrief,asinternal
standard 15 pmol of ubihydroquinone-9 in 50μL ethanol
were added to a 100μLm o n o c y t eo rl i v e rh o m o g e n a t e
suspension. The cells and homogenates were disintegrated
by adding of 300μL of cold methanol. Subsequently, the
sample was mixed for 1 minute, and the suspension was
immediately extracted with 500μL hexane after mixing for
further 2minutes. After centrifugation (1000 xg, 5minutes,
4◦C),300μLofthesupernatantweretransferredtoaseparate
tube and dried under a stream of argon. Finally, the dried
residue was redissolved in 40μL ethanol and injected into
the HPLC system. For each liver homogenate sample, the
analyzed CoQ10 concentration was related to its respective
protein level.
2.6. Protein Quantiﬁcation of Liver Homogenate Solutions.
For calculation of diﬀerences in sample preparation, protein
concentration was determined in liver homogenate samples
(in μg/ml). Thus, homogenate samples were collected into
NET-buﬀer (50mM TRIS [pH 7.5], 150mM NaCl, 1mM
EDTA [pH 8.0], 0.5% NP-40). In each case, homogenate
solutions were treated with ultrasonics (“n” vs. “m”) and
then centrifuged by 14.000rpm at 4◦Cf o r2 0 m i n u t e s .Mediators of Inﬂammation 3
Table 1: Concentration and redox state of CoQ10 in the human monocytic cell line THP-1 after incubation with various concentrations of
ubiquinol-10 for 24 hours. Data are given as means ± SD of two independent measurements performed in duplicate.
Extracellular Cellular
μM ubiquinol-10 pmol CoQ10/106 cells % ubiquinol-10 μM ubiquinol-10((a)-(b))
0, medium control 25.62 ±4.42 74.40 ±0.14 4.56
0, vehicle control 23.07 ±0.46 74.70 ±1.56 4.12
0.1 24.68 ±2.01 75.25 ±0.35 4.44
1.0 26.48 ±3.36 79.35 ±0.07 5.03
10.0 72.35 ±1.14 86.10 ±0.71 14.90
100 627.46 ±138.08 90.35 ±1.48 140.35
(a)Suggested diameter of monocytes: 20μm
(b)Related to mean values.
The protein concentration was determined by the Bradford
method according to the manufacturer’s instructions.
2.7. RNA Isolation and Quantitative RT-PCR of THP-1 Cells.
Total RNA was isolated by using the miRNeasy Isolation Kit
(Qiagen, Germany), and cDNA was converted by the Taq-
ManMicroRNA Reverse Transcription Kit (Applied Biosys-
tems).miRNA-146aexpressionwasmeasuredandquantiﬁed
byusingtheTaqManMicroRNAAssays(AppliedBiosystems)
according to the manufacturer’s protocol and normalised
by snoRNA202 (Applied Biosystems). Quantitative RT-PCR
reactionwasperformedonanAppliedBiosystems7300Real-
Time PCR System.
2.8.RNAIsolationofLiverSamplesandQuantitativeRT-PCR.
Total RNA was isolated with Qiazol lysis reagent obtained
with the miRNeasy Isolation Kit (Qiagen, Germany). cDNA
was converted by the TaqMan MicroRNA Reverse Transcrip-
tion(RT)Kit(AppliedBiosystems).TheRTreactionproduct
was diluted 10 times in water and subsequently used for
RT-PCR ampliﬁcation of miRNA-146a by using the TaqMan
MicroRNA Assays (Applied Biosystems) according to the
manufacturer’s protocol and normalized by snoRNA202
(Applied Biosystems). A 6-fold total RNA-dilution series
fromacontrol-treated(+LPS)mouseliverservedasstandard
to ensure a linear range of the ampliﬁcation. Quantitative
RT-PCR reaction was performed on an Applied Biosystems
7300 Real-Time PCR System.
2.9. Statistics. Results were analyzed by an unpaired, two- or
one-sided Student’s t-test using SPSS 11.5 for Windows and
GraphPad Prism 4.0 software. P-values less than or equal to
.05 were considered statistically signiﬁcant.
3. Results andDiscussion
3.1. No Cytotoxic Eﬀects but Cellular Accumulation of
Ubiquinol-10 in the Human Monocytic Cell Line THP-1. To
exclude cytotoxic side eﬀects in our experimental set-up,
vitality of THP-1 cells was determined after incubation with
ubiquinol-10. As shown in Figure 1, incubation of THP-
1 cells with increasing ubiquinol-10 concentrations (0.1–
100μM) for 24hours led to no signiﬁcant eﬀects on cell
vitality. Thus, in THP-1 cells no cytotoxicity was found
for ubiquinol-10 at physiological (1.0μM), supraphysio-
logical (10μM), and pharmacological (>10μM) concen-
trations. The putative eﬀects of extracellular ubiquinol-
10 on miR expression depend on its capability to reach
cellular concentrations above background level. Therefore,
we determined the cellular concentration of CoQ10 as a
function of medium ubiquinol-10. As shown in Table 1,
cellular CoQ10 levels arose with increasing extracellular
ubiquinol-10 concentrations (0.1–100μM). As mainly the
reduced form of CoQ10 can function as an antioxidant
[11], we determined the proportion between the oxidized
and reduced form of CoQ10. Depending on the extracel-
lular ubiquinol-10 concentration, about 75–90% of cellular
CoQ10 was present in its reduced form (Table 1). Moreover,
our previous results have shown that monocytic cellsare able
to convert oxidized CoQ10 eﬀectively into its reduced form
[12]. Thus, at physiological and supraphysiological CoQ10
levels in the medium (0.1–10μM), the intracellular CoQ10
distribution is clearly in favor of the reduced form (75–
90%). Other in vitro and in vivo studies also revealed an
intracellular incorporation of CoQ10 after supplementation
in blood cells, thereby leading, for example, to a reduction
of DNA strand breakdowns [11, 13]. Taken together, we
were able to increase the cellular ubiquinol-10 concentra-
tion without any cytotoxic side-eﬀects in human THP-1
cells.
3.2. Ubiquinol-10 Attenuates the LPS-Induced Expression of
miR-146aintheHumanMonocyticCellLineTHP-1. In order
to study the eﬀect of ubiquinol-10 on LPS-induced miR-
146a expression, appropriate conditions were established.
For this purpose, the LPS-induced response of THP-1 cells
was examined. Unstimulated THP-1 cells did not secrete
relevant amounts of TNF-α into the medium (4.22pg/mg
protein ± SD). However, stimulation with 1μg/mL LPS
for 4hours resulted in an increase of medium TNF-α
levels (351.94pg/mg protein ± SD). Thus, we obtained a
substantialandanticipatedLPS-responseofTHP-1cells[14].
As already described in the literature [7], the expression level
of miR-146a is upregulated by LPS. As shown in Figure 2,
in comparison to unstimulated THP-1 cells, LPS challenge
induced a 19-fold induction of miR-146a expression (P =
.0007). With respect to our results regarding cytotoxicity4 Mediators of Inﬂammation
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Figure 2: Eﬀect of ubiquinol-10 on LPS-induced miR-146a expres-
sion in THP-1 cells. THP-1-cells were preincubated without (−)o r
with (+) 10μM ubiquinol-10 for 24hours. Afterwards, cells were
treated without (−) or with (+) 1μg LPS/mL for 4hours. After this
treatment, total RNA was extracted, converted to cDNA and miRs
were assayed by TaqMan-based qRT-PCR. Observed expression
levels of miRs in the respective treated cells were normalized to the
correspondinglevelsoftheendogenouscontrol(snoRNA202).Data
(two-sided t-test) are means ± SEM of three biological experiments
performed in quadruplicate. ∗P<. 05 versus unstimulated cells.
∗∗∗P<. 001 versus unstimulated cells.
and cellular accumulation of ubiquinol-10, THP-1 cells were
preincubated with 10μM ubiquinol-10 for 24hours as an
eﬀective dose. This is nearly in accordance to other in
vitro studies performed with CoQ10 [15, 16] and is only 2-
fold higher than CoQ10 serum levels after supplementation
in humans [17]. Thereafter, cells were stimulated with
1μg/mL LPS for 4hours and the resulting steady-state
expression level of miR-146a was determined. As shown in
Figure 2, preincubation of THP-1 cells with ubiquinol-10
reduced the LPS-induced expression level of miR-146a to
78.9 ± 13.22%. Although these eﬀects were not statistically
signiﬁcant (P ≤ .05), the reduced expression levels of miR-
146aintheubiquinol-10-pretreatedcells(QH2 +LPS)might
be a ﬁrst hint for a ﬁne-tuning mechanism of QH2 on
miR-146a expression when compared to the high signiﬁ-
cant induction levels in control cells after LPS-stimulation
(Veco LPS).
3.3. Accumulation of CoQ10 Levels in the Liver of Ubiquinol-
10 Supplemented Mice. To test putative eﬀects of CoQ10 on
miRNA 146a regulation in a more physiological manner,
liver tissues of QH2-supplemented C57BL6/J mice were
used. However, to mediate these eﬀects, a tissue-speciﬁc
accumulation of CoQ10 is essential. Therefore, total CoQ10
levels were determined in liver homogenate samples of QH2-
supplemented and control mice. As shown in Figure 3(a),
total CoQ10 levels increased about 12-fold (P = .0193)
in liver tissues of QH2-supplemented mice when related to
control samples. Because CoQ9 is the predominant CoQ
form in rodents [18], CoQ9 was used as an internal standard
forHPLC-analysis.Thus,theCoQ9 levelwasnotsigniﬁcantly
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Figure 3: Eﬀect of ubiquinol-10 concentration (a) on CoQ10
levels and (b) the CoQ9/CoQ10 ratio in liver tissues of mice.
Mice were fed with ubiquinol-10 (250mg/kg/d) or a respective
control diet (no ubiquinol-10 supplement) for 7 days followed
by a sublethal intraperitoneal injection with saline (0.9% NaCl,
LPS negative control) for further 4hours. Thereafter, liver samples
were collected, homogenized, and used for HPLC analysis with
electrochemical detection. CoQ9 was used as an internal standard.
Observed CoQ levels were related to the corresponding protein
levels of the respective liver homogenate samples (single data not
shown). All data (one-sided t-test) are means ± SEM of 5 animals
in the intervention group (+QH2) and control group (−QH2),
respectively. Protein-related CoQ10 levels and CoQ9/CoQ10 ratio
of ubiquinol-10-supplemented and control animals are depicted in
Figures 3(a) and 3(b),r e s p e c t i v e l y .
changedbetweentreatmentandcontrolgroup(P = .51, data
not shown). Accordingly, the CoQ9/CoQ10 ratio was signiﬁ-
cantly diﬀerent between groups, corresponding to a 6.5-fold
increase in control tissue samples (P = .0019, Figure 3(b)).
In general, all HPLC measurements were related to pro-
tein levels in the respective tissue homogenate samples.
In summary, we could signiﬁcantly increase the CoQ10
concentration in liver tissues of ubiquinol-10-supplemented
mice. An eﬀective uptake of exogenously applied CoQ10 in
liver tissues of rodents has been already described earlier
[19].Mediators of Inﬂammation 5
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Figure 4: Eﬀect of ubiquinol-10 supplementation on miR-146a
expression in liver samples of LPS-treated mice. Mice were fed
with ubiquinol-10 (250mg/kg/d) or a respective control diet (no
ubiquinol-10 supplement) for 7 days. Afterwards, a sublethal
intraperitonealinjectionofLPS(1mg/kgBW)wasadministeredfor
further 4hours Thereafter, liver samples were collected, homoge-
nized, and total RNAs including miRs were isolated as described by
themanufacturer’sinstructions.Subsequently,miRswereconverted
to cDNA and assayed by the TaqMan-based qRT-PCR. Observed
miR-146a expression levels of each animal were related to the
correspondinglevelsoftheendogenouscontrol(snoRNA202).Data
(two-sidedt-test)aremeans ±SEMof6animalsintheintervention
group (+QH2/+LPS) and control group (+LPS), respectively. miR-
146a expression levels are depicted as single bars of each animal
(Figure 4(a)) or as total mean ± SEM of each group (Figure 4(b)).
3.4. Reduced Expression Levels of miR-146a in Liver Tissues
of Ubiquinol-10-Supplemented Mice. To test the relevance
of a putative ubiquinol-10-dependent downregulation of
LPS-inducible miR-146a expression in vivo, we used mice
receiving either a diet enriched with ubiquinol-10 (QH2,
250mg/kg/d) or a respective control diet for seven days.
This dosage is in accordance with previous CoQ10 studies
in mice [20–22]. Thereafter, an intraperitoneal injection of
lipopolysaccharide (LPS, 1mg/kg BW) was administered for
further 4hours. In contrast to the control non-LPS-injected
mice (no detectable TNF-α levels), TNF-α levels increased
signiﬁcantly in the serum of LPS-treated animals (612.46
± SD). Finally, mice were sacriﬁced and livers were col-
lected for miR isolation and determination of miRNA-146a
expression levels. As shown in Figure 4(a), the LPS-induced
expression level of miR-146a is generally lower in animals
supplemented with ubiquinol-10. In average, ubiquinol-10
reduces the LPS-induced miR-146a expression to 78.12 ±
21.25% (+QH2/+LPS) when compared to control animals
(−QH2/+LPS) (Figure 4(b)). This eﬀect was statistically not
signiﬁcantbutwasconsistenttothoseobtainedincellculture
experiments.
Regulation of miRs by certain compounds or nutrients is
of general interest, because this class of noncoding RNAs is
involved in central biological processes such as development,
inﬂammation and innate immunity, and signalling networks
[1, 23]. So far, only a small number of environmental mod-
ulators of miR expression have been identiﬁed. Expression
levels of several miRs (i.e., miR-15a/b, miR-16, miR-107) are
regulated by retinoic acid-induced diﬀerentiation in human
acute promyelocytic leukemia patients and cell lines [24].
Compounds such as sulphate, phosphate, and amino acids
regulate the expression of special miRs in plants [25]a n d
human liver cells [26]. Toll-like receptor (TLR) ligands such
as LPS induce the expression of miR-146a signiﬁcantly in
human monocytes/macrophages [7].
4. Conclusion
Here we identiﬁed ubiquinol-10 as a putative modulator
of miR-146a expression. Preincubation of THP-1 cells
with ubiquinol-10 reduced the LPS-induced expression
level of miR-146a. These results are consistent to our in
vivo data, where the expression of miR-146a was reduced
in liver samples of mice supplemented with ubiquinol-
10 before LPS-injection (+QH2/+LPS) when compared to
control animals (+LPS). Although the observed eﬀects are
statistically not signiﬁcant, we postulated a ﬁne-tuning
mechanism of ubiquinol-10 on the inﬂammatory response
via a moderate reduction of miR-146a expression. According
to the superior function of miR-146a in the inﬂammatory
response, the observed moderate reduction of its expression
by ubiquinol-10 seems to be desirable based on the following
mechanisms. First, the LPS induced upregulation of miR-
146a in human monocytes/macrophages functions as a
negative regulator of the innate immune response because
miR-146a targets TRAF6, a regulator protein within the
TLR-signalling pathways involved in the formation and
accumulation of reactive oxygen species [7]. Second, we
have recently shown that ubiquinol-10 lowers the LPS-
stimulated release of some proinﬂammatory cytokines and
chemokines relevant in inﬂammatory processes [27]. The
observed eﬀects were comparable to those of the potent
and characterized antioxidants N-acetyl-cysteine (NAC) or
pyrrolidine-dithiocarbamate(PDTC)[12,14,27].Moreover,
mir-146a has been shown to be induced by proinﬂammatory6 Mediators of Inﬂammation
cytokines such as TNF-α, interleukin 1-beta (IL-1β), and
TLRs [7, 28, 29]. miR-146a was also detected in tissues
relatedtoinﬂammatorydiseasesincluding, forexample,syn-
ovial ﬁbroblasts and rheumatoid synovial tissue [28]. Thus,
we conclude that ubiquinol-10 reduces both the secretion
of proinﬂammatory agents and the expression of the anti-
inﬂammatory miR-146a. As a consequence, ubiquinol-10
acts as an anti-inﬂammatory compound but perpetuates
the essential inﬂammatory response via moderate reduction
of miR-146a expression. This dual eﬀect could be due
to the radical scavenging activity of ubiquinol-10 since
reactive oxygen species are involved in the TLR-signalling
pathways.
In conclusion, the consistent in vitro and in vivo data
suggest that ubiquinol-10 may ﬁne-tune the inﬂammatory
response via moderate reduction of miR-146a expression.
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